-
Mashup Score: 12In Brief for May 28, 2025 - ILCN.org (ILCN/WCLC) - 2 day(s) ago
The US FDA grants accelerated approval to telisotuzumab vedotin-tllv for advanced NSCLC with high c-Met overexpression.
Source: www.ilcn.orgCategories: General Medicine NewsTweet
-
Mashup Score: 22PACLC 2025 Highlights | IASLC - 3 day(s) ago
This session will highlight key topics from the conference, including lung cancer epidemiology in Africa, barriers to diagnosis and treatment, and the evolving …
Source: www.iaslc.orgCategories: General Medicine NewsTweet-
🌍 What does lung cancer care look like across Africa? Join our upcoming webinar to explore: ✅ Barriers to treatment & diagnosis ✅ Clinical trials in Sub-Saharan Africa ✅ Advocacy & access in low-resource settings 🗓️ Register now: https://t.co/gEq9QFQ0nn #PACLC25 #IASLC https://t.co/TW4niRRdB1
-
-
Mashup Score: 352025 ASCO Highlights | IASLC - 4 day(s) ago
Join us for an exclusive webinar that delves into the most groundbreaking studies and updates presented at the 2025 American Society of Clinical Oncology (ASCO) …
Source: www.iaslc.orgCategories: General Medicine NewsTweet-
Curious about highlights from #ASCO25? Join us on June 27 for the latest on NSCLC & SCLC breakthroughs, neoadjuvant immunotherapy, EGFR strategies & more. 🎓 1 CME credit available. 👉 Register: https://t.co/3uRkBH93Jd #ASCO25 #LungCancer #CME #Oncology #LCWEBINARS https://t.co/sVTB26khIl
-
-
Mashup Score: 28
This webinar presents a multidisciplinary tumor board format to explore the management of complex Stage III and IVa thymomas. It will address current gaps by of …
Source: www.iaslc.orgCategories: General Medicine NewsTweet-
Join @JVelottaMD, @aparna96, and other experts from around the world as they guide you through real-world management of Stage III & IVa thymomas in next week's webinar. 🎓 See the full speaker lineup + register here: https://t.co/85wM4nWwWr #Thymoma #OncologyWebinar https://t.co/BYVTAFJdFF
-
-
Mashup Score: 12
Author Dr. David Spigel says these findings may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery.
Source: www.ilcn.orgCategories: General Medicine NewsTweet-
.@DavidRSpigel says a 14-gene molecular assay may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery. 🔗 Read more: https://t.co/Pf1mMYNQPA
-
-
Mashup Score: 0Falling Through the Cracks: Battling Barriers in Lung Cancer Care - ILCN.org (ILCN/WCLC) - 6 day(s) ago
California firefighter Daiyo Ito says that while the Los Angeles County wildfires brought increased health risks for his mother, the biggest obstacle to her care and treatment was navigating her lung cancer diagnosis within a broken healthcare system.
Source: www.ilcn.orgCategories: General Medicine NewsTweet-
A California firefighter recounts his mother's lung cancer diagnosis journey before and during the LA Wildfires in January 2025. 🔗 Read more: https://t.co/QJGa4UT2UT
-
-
Mashup Score: 24
NACLC 2025 is the must-attend event for anyone committed to advancing lung cancer care. This year’s meeting will spotlight the latest in clinical research, early detection, and breakthrough therapies—while bringing together a diverse community of experts. Registration, Abstract & Education Award Submission Opens Tell your customers about new website functionality! Discover cutting-edge treatments and technologies Collaborate with leading clinicians, researchers, and advocates Explore strategies to advance
Source: www.naclc-iaslc.orgCategories: General Medicine NewsTweet-
📅 Save the date! The IASLC | @ASCO North America Conference on Lung Cancer (#NACLC25) will take place December 5–7 in Chicago. Don’t miss cutting-edge research on early detection, breakthrough therapies, and more at this premier event. Learn more ➡️ https://t.co/cLqooVUGgT https://t.co/8iPqKZdCPY
-
-
Mashup Score: 23#HT25 - HT25 - 9 day(s) ago
HT25 is your chance to engage with a diverse, international community of scientists, clinicians, diagnosticians, industry leaders, and data experts. This is a rare opportunity to form collaborations that bridge basic research, translational science, and clinical innovation in early lung cancer. Stay Ahead in Early Lung Cancer Research Gain cutting-edge insights into the molecular, genomic, transcriptomic, and immune mechanisms that drive early lung carcinogenesis. Advance Biomarker and Diagnostic Innovation
Source: fallht-iaslc.orgCategories: General Medicine NewsTweet-
📢 Save the Date! The IASLC 2025 Hot Topic Meeting is coming to Tokyo, Nov 21–23! 🧬 Focus: Early lung carcinogenesis, emerging biomarkers & new therapeutic targets. Join leading researchers, clinicians & oncology experts. 🔗 https://t.co/a909sc1H9m #HT25 #IASLC #LungCancer https://t.co/gfe86g1q49
-
-
Mashup Score: 17
Dana-Farber’s Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space.
Source: www.ilcn.orgCategories: General Medicine NewsTweet-
#AACR25 Recap: Dr. Alice Shaw highlights promising combination strategies in overcoming KRAS resistance. 🔗 Read more in ILCN: https://t.co/p2XBHpQcKg
-
-
Mashup Score: 38Virtual Tumor Board: Targeting Residual Disease | IASLC - 10 day(s) ago
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Mara Antonoff, Dr. Shankar Siva, and Dr. David Car …
Source: www.iaslc.orgCategories: General Medicine NewsTweet-
Can ablative therapy play a role in treating residual disease in stage IV #NSCLC? On #LungCancerConsidered, @StephenVLiu joins @MaraAntonoff, @_ShankarSiva & @DCarboneMD to discuss a complex case and evolving treatment strategies. 🎧 Listen now: https://t.co/VHKf8ScAgM https://t.co/jjIkD7uArd
-
#ICYMI: Telisotuzumab vedotin-tllv receives accelerated FDA approval for advanced NSCLC with high c-Met overexpression. 📰 Read more in ILCN: https://t.co/wcWrLmPY5e